Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 52

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1A
Chunk 52
---
 ●
    the success of competitive products or technologies;

    ●
    regulatory actions with respect to our product candidates or products or our competitors’ product candidates or products;

47

    ●
    actual or anticipated changes in our growth rate relative to our competitors;

    ●
    announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations, or capital commitments;

    ●
    results of clinical studies of our product candidates or those of our competitors;

    ●
    regulatory or legal developments in the U.S. and other countries;

    ●
    developments or disputes concerning patent applications, issued patents or other proprietary rights;

    ●
    the recruitment or departure of key personnel;

    ●
    the level of expenses related to any of our product candidates or clinical development programs;

    ●
    the results of our efforts to in-license or acquire additional product candidates or products;

    ●
    actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;

    ●
    variations in our financial results or those of companies that are perceived to be similar to us;

    ●
    fluctuations in the valuation of companies perceived by investors to be comparable to us;

    ●
    inconsistent trading volume levels of our shares;

    ●
    announcement or expectation of additional financing efforts;

    ●
    sales of our Common Stock by us, our insiders or our other stockholders;

    ●
    market conditions in the pharmaceutical and biotechnology sectors;

    ●
    general economic, industry and market conditions; and

    ●
    the other risks described in this “Risk Factors” section.

In addition, the stock markets
in general, and the markets for biotechnology, pharmaceutical and technology stocks in particular, have experienced significant volatility
that has often been unrelated to the operating performance of particular companies.

Sales of a substantial number of shares of our
Common Stock in the public market could cause our stock price to fall.

The market price of our Common
Stock could decline as a result of substantial sales of our Common Stock in the public market, or the perception that such sales could
occur. Because the majority of our outstanding shares of Common Stock are registered and unrestricted, they may be sold in the public
market at any time. Any such sales, or the availability of those shares for sale, could adversely affect the trading price of our Common
Stock and make it more difficult for us to raise capital through future equity offerings. In addition, a decline in the